IST effective against inflammation

Article

Immunosupressants are an effective in controlling ocular inflammation caused by severe or steroid-resistant autoimmune disease, according to study results published online ahead of print by Acta Ophthalmologica.

Immunosupressants are an effective in controlling ocular inflammation caused by severe or steroid-resistant autoimmune disease, according to study results published online ahead of print by Acta Ophthalmologica.

Paolo Mora, MD of the University of Parma, Italy and colleagues conducted a prospective, non-randomized study of patients with ocular inflammation (n=76; eyes, n=121) who, after 9±2 months of non-response to monotherapy, switched to a combined immunosuppressive treatment (IST) protocol in which all treatments (including steroids) were administered discontinuously for 43±15 months.

Complete inflammation control was achieved in 86% of patients; the rate of inflammatory events per patient was 0.78±1.13 in the first year of treatment, and the rare continued to decrease throughout the follow-up period. Mean best-corrected visual acuity (BCVA) increased to 0.24 logMAR after follow-up from 0.31 logMAR at baseline. Despite these visual improvements, patients' blood pressure and uric acid blood levels worsened significantly during the study period.

The researchers concluded that IST offers long-term improvements in the rate of inflammatory events and decreases the need for steroid treatment.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jay Chhablani, MD, shares late-breaking data from the ArMaDa trial, investigating gene therapy for Geographic Atrophy and dry age-related macular degeneration, at EURETINA
Editorial advisory board member Alexandra Miere, MD, PhD, speaks about the ACTOR and HERMES studies at the 2025 European Society of Retina Specialists (EURETINA) Congress
María Berrocal, MD, speaks about the Vit-Buckle Society symposium hosted at the 2025 European Society of Retina Specialists (EURETINA) annual meeting
© 2025 MJH Life Sciences

All rights reserved.